<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769611</url>
  </required_header>
  <id_info>
    <org_study_id>2013-7007</org_study_id>
    <nct_id>NCT02769611</nct_id>
  </id_info>
  <brief_title>Ruboxistaurin in New York Heart Failure Classification III-IV Patients</brief_title>
  <official_title>A Prospective Phase I/II Dose Escalation Pilot Analysis of Ruboxistaurin (LY333531) for Safety in New York Heart Failure Classification III-IV Patients, As Well As For Efficacy in Acutely Augmenting Cardiac Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Christ Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of ruboxistaurin for its safety, tolerability, and&#xD;
      effectiveness in treating adult patients with heart failure. Patients will receive 1 dose of&#xD;
      oral ruboxistaurin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ruboxistaurin is a drug initially developed for treatment of diabetic peripheral retinopathy.&#xD;
      The proposed indication for ruboxistaurin in this study is the treatment of adult patients&#xD;
      with New York Heart Failure Association (NYHA) Class III-IV heart failure. Ruboxistaurin is a&#xD;
      protein kinase c-alpha (PKC-alpha) inhibitor and thus will produce an inotropic effect in the&#xD;
      heart which holds the potential to improve cardiac function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients with a new onset, clinically significant arrhythmia or conduction system disease,</measure>
    <time_frame>48 hours</time_frame>
    <description>EKG and continuous holter monitoring will be performed. Determination of clinically significant arrhythmia will be determined by a blinded electrophysiologist; intent to treat population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of patients with significant prolongation in the corrected QT (QTc) interval</measure>
    <time_frame>24 hours</time_frame>
    <description>Interpreted by a blinded electrophysiologist. A significant QTc prolongation will be defined as an increase from normal baseline (&lt;440 msec) to greater than 440 msec OR an increase of equal to or more than 5% from baseline for those subjects with a baseline QTc of &gt;440 msec.; Intent to treat population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of patients with significant increase in liver function tests</measure>
    <time_frame>12 hours</time_frame>
    <description>An abnormal change in liver function tests will be defined as an increase to 2x the upper limits of normal for aspartate aminotransferase (AST) and alanine aminotransferase (ALT) OR a 50% increase from baseline values. Intent to treat population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of patients with a significant increase in serum creatinine not explained by diuretic use.</measure>
    <time_frame>12 hours</time_frame>
    <description>An abnormal change in serum creatinine will be defined as a 50% increase from baseline values. Of note, changes in Blood Urea Nitrogen (BUN) and creatinine may be secondary to diuretic use and intravascular volume depletion. Intent to treat population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of patient with a significant increase in serum creatine phosphokinase (CPK) levels</measure>
    <time_frame>12 hours</time_frame>
    <description>An abnormal change in serum CPK will be defined as an increase to 2x the upper limits or normal OR a 50% increase from baseline values. Intent to treat population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients experiencing at least one adverse event</measure>
    <time_frame>30 days</time_frame>
    <description>Adverse events will be assessed up to 30 days post study drug administration. Intent to treat population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiac contractility as assessed by echocardiography.</measure>
    <time_frame>4 hours</time_frame>
    <description>Transthoracic echocardiogram performed at baseline and 4 hours. Intent to treat population. Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self-reported well-being, fatigue and dyspnea</measure>
    <time_frame>8 hours, 24 hours</time_frame>
    <description>All subjects will undergo assessment of self-reported global well-being, fatigue and dyspnea via a visual-analogue scale that ranges from 0-100. Intent to treat population</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ruboxistaurin 64 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ruboxistaurin, 64 mg as 1 capsule by mouth with water, 1 time administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ruboxistaurin 128 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ruboxistaurin, 128 mg as 2 capsules by mouth with water, 1 time administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ruboxistaurin 256 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ruboxistaurin, 256 mg as 4 capsules by mouth with water, 1 time administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruboxistaurin</intervention_name>
    <description>Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.</description>
    <arm_group_label>Ruboxistaurin 128 mg</arm_group_label>
    <arm_group_label>Ruboxistaurin 256 mg</arm_group_label>
    <arm_group_label>Ruboxistaurin 64 mg</arm_group_label>
    <other_name>LY333531</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, 30-75 years of age, inclusive&#xD;
&#xD;
          2. NYHA Class III-IV heart failure (HF) confirmed left ventricular systolic dysfunction&#xD;
             with left ventricular ejection fraction (LVEF) &lt;40% as assessed by noninvasive imaging&#xD;
             studies such as echocardiography or cardiac MRI within the last 6 months admitted with&#xD;
             decompensated heart failure and almost ready for clinical discharge&#xD;
&#xD;
          3. Patient must have had adequate therapy for acute decompensated HF (heart failure)&#xD;
             episode prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with acute coronary syndrome&#xD;
&#xD;
          2. Resynchronization therapy initiated less than 90 days prior to enrollment&#xD;
&#xD;
          3. (LVAD) left ventricular assist device or heart transplantation expected within the&#xD;
             next 3 months&#xD;
&#xD;
          4. Patients on hemodialysis or end stage renal disease (ESRD)&#xD;
&#xD;
          5. Patients with serum albumin less than 3 g/dL or evidence of liver cirrhosis&#xD;
&#xD;
          6. Patients with uncontrolled arterial hypertension (systolic blood pressure &gt; 180 or&#xD;
             diastolic blood pressure &gt;110)&#xD;
&#xD;
          7. Patients with severe valvular heart disease&#xD;
&#xD;
          8. Patients with acute myocarditis&#xD;
&#xD;
          9. Patients with serum creatinine &gt;3.0 mg/dl or BUN &gt;70 mg/dL&#xD;
&#xD;
         10. Patients with hemodynamic instability or significant active arrhythmias&#xD;
&#xD;
         11. Patients currently on intravenous inotropic therapy or those that have received&#xD;
             inotropic therapy within the last 24 hours prior to study enrollment&#xD;
&#xD;
         12. Patients currently on CYP3A inhibitors, or patients that have taken CYP3A inhibitors&#xD;
             within 3 months prior to enrollment&#xD;
&#xD;
         13. Patients with ongoing ischemia&#xD;
&#xD;
         14. Patients who have had a myocardial infarction within 30 days prior to study enrollment&#xD;
&#xD;
         15. Patients who are pregnant, nursing, or planning to become pregnant during the study&#xD;
             period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Jefferies, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Jefferies, MD</last_name>
    <phone>(513)803-1675</phone>
    <email>j.jefferies@cchmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Egnaczyk, MD</last_name>
      <phone>513-585-1777</phone>
    </contact>
    <investigator>
      <last_name>Gregory Egnaczyk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 10, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ruboxistaurin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

